What is the equity of AnGes this year?
AnGes has equity of 26.1 B JPY this year.
AnGes Equity 2024
AnGes Equity
26.1 B JPY
Ticker
4563.T
ISIN
JP3127700007
WKN
779518
In 2024, AnGes's equity was 26.1 B JPY, a -14.21% increase from the 30.43 B JPY equity in the previous year.
AnGes Aktienanalyse
What does AnGes do?
AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing AnGes's Equity
AnGes's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AnGes's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating AnGes's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
AnGes's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in AnGes’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about AnGes stock
What was the equity of AnGes compared to the previous year?
The equity of AnGes has increased/decreased by -14.21% decreased compared to the previous year.
What impact does a high equity have on investors of AnGes?
A high equity is advantageous for investors of AnGes as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of AnGes?
A low equity can be a risk for investors of AnGes, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of AnGes affect the company?
An increase in equity of AnGes can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of AnGes affect the company?
A reduction in equity of AnGes can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of AnGes?
Some factors that can affect the equity of AnGes include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of AnGes so important for investors?
The equity of AnGes is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can AnGes take to change the equity?
To change equity, AnGes can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does AnGes pay?
Over the past 12 months, AnGes paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnGes is expected to pay a dividend of 0 JPY.
What is the dividend yield of AnGes?
The current dividend yield of AnGes is .
When does AnGes pay dividends?
AnGes pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnGes?
AnGes paid dividends every year for the past 0 years.
What is the dividend of AnGes?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnGes located?
AnGes is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnGes kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnGes from 10/28/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.
When did AnGes pay the last dividend?
The last dividend was paid out on 10/28/2024.
What was the dividend of AnGes in the year 2023?
In the year 2023, AnGes distributed 0 JPY as dividends.
In which currency does AnGes pay out the dividend?
The dividends of AnGes are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnGes
Our stock analysis for AnGes Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnGes Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
